tiprankstipranks
Monopar Therapeutics Inc (DE:1IY0)
NASDAQ:1IY0
Germany Market
1IY0
Monopar Therapeutics Inc
RESEARCH TOOLSreports

Monopar Therapeutics Inc (1IY0) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1IY0 Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Monopar
Therapeutics Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1IY0 Stock 12 Month Forecast

Average Price Target

€104.62
▲(14.85% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Monopar Therapeutics Inc in the last 3 months. The average price target is €104.62 with a high forecast of €114.88 and a low forecast of €87.24. The average price target represents a 14.85% change from the last price of €91.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"€27","49":"€49","71":"€71","93":"€93","115":"€115"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":114.88146852,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€114.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104.62419454500001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€104.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.24081444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€87.24</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,49,71,93,115],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.9,99.20626680923077,100.51253361846155,101.81880042769231,103.12506723692309,104.43133404615385,105.73760085538461,107.04386766461539,108.35013447384615,109.65640128307692,110.9626680923077,112.26893490153846,113.57520171076924,{"y":114.88146852,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.9,98.41724573423078,98.93449146846154,99.45173720269231,99.96898293692308,100.48622867115385,101.00347440538462,101.52072013961539,102.03796587384616,102.55521160807693,103.0724573423077,103.58970307653847,104.10694881076924,{"y":104.62419454500001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.9,97.08006264923077,96.26012529846155,95.44018794769231,94.62025059692309,93.80031324615385,92.98037589538461,92.16043854461539,91.34050119384615,90.52056384307691,89.70062649230769,88.88068914153845,88.06075179076923,{"y":87.24081444,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.9,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€114.88Average Price Target€104.62Lowest Price Target€87.24
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:1IY0
Maxwell Skor
Morgan Stanley
Morgan Stanley
€99.33→€112.29
Buy
23.26%
Upside
Assigned
08/17/26
Morgan Stanley Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)
Barclays Analyst forecast on DE:1IY0
Etzer Darout
Barclays
Barclays
€107.97→€110.56
Buy
21.36%
Upside
Reiterated
08/13/26
Barclays Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
H.C. Wainwright Analyst forecast on DE:1IY0
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
€107.97
Buy
18.52%
Upside
Reiterated
08/13/26
Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained
JonesTrading Analyst forecast on DE:1IY0
Boris Peaker
JonesTrading
JonesTrading
€112.29
Buy
23.26%
Upside
Reiterated
08/12/26
Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile
BTIG Analyst forecast on DE:1IY0
Jeet Mukherjee
BTIG
BTIG
€101.06→€114.88
Buy
26.10%
Upside
Reiterated
08/12/26
Analysts Are Bullish on Top Healthcare Stocks: Monopar Therapeutics Inc (MNPR), AbSci (ABSI)
Cantor Fitzgerald Analyst forecast on DE:1IY0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€94.15→€102.79
Hold
12.83%
Upside
Downgraded
08/12/26
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (NASDAQ: MNPR), Achieve Life Sciences (NASDAQ: ACHV) and OptimizeRx (NASDAQ: OPRX)
Lake Street Analyst forecast on DE:1IY0
Chad Messer
Lake Street
Lake Street
€88.97
Buy
-2.34%
Downside
Reiterated
06/30/26
Monopar Therapeutics Inc (MNPR) Gets a Buy from Lake Street
Piper Sandler Analyst forecast on DE:1IY0
Biren Amin
Piper Sandler
Piper Sandler
€87.24
Buy
-4.24%
Downside
Reiterated
06/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on DE:1IY0
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€99.33
Buy
9.04%
Upside
Reiterated
05/15/26
Leerink Partners Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)
Raymond James Analyst forecast on DE:1IY0
Christopher Raymond
Raymond James
Raymond James
€122.66→€106.24
Buy
16.62%
Upside
Reiterated
11/14/25
Monopar downgraded to Outperform from Strong Buy at Raymond JamesMonopar downgraded to Outperform from Strong Buy at Raymond James
Chardan Capital Analyst forecast on DE:1IY0
Keay Nakae
Chardan Capital
Chardan Capital
€51.83→€73.42
Buy
-19.41%
Downside
Reiterated
09/25/25
Monopar Therapeutics price target raised to $85 from $60 at ChardanMonopar Therapeutics price target raised to $85 from $60 at Chardan
Brookline Capital Markets Analyst forecast on DE:1IY0
Kemp Dolliver
Brookline Capital Markets
Brookline Capital Markets
€44.92→€80.33
Buy
-11.82%
Downside
Reiterated
09/25/25
Brookline Capital Markets Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:1IY0
Maxwell Skor
Morgan Stanley
Morgan Stanley
€99.33→€112.29
Buy
23.26%
Upside
Assigned
08/17/26
Morgan Stanley Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)
Barclays Analyst forecast on DE:1IY0
Etzer Darout
Barclays
Barclays
€107.97→€110.56
Buy
21.36%
Upside
Reiterated
08/13/26
Barclays Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)
H.C. Wainwright Analyst forecast on DE:1IY0
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
€107.97
Buy
18.52%
Upside
Reiterated
08/13/26
Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained
JonesTrading Analyst forecast on DE:1IY0
Boris Peaker
JonesTrading
JonesTrading
€112.29
Buy
23.26%
Upside
Reiterated
08/12/26
Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile
BTIG Analyst forecast on DE:1IY0
Jeet Mukherjee
BTIG
BTIG
€101.06→€114.88
Buy
26.10%
Upside
Reiterated
08/12/26
Analysts Are Bullish on Top Healthcare Stocks: Monopar Therapeutics Inc (MNPR), AbSci (ABSI)
Cantor Fitzgerald Analyst forecast on DE:1IY0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€94.15→€102.79
Hold
12.83%
Upside
Downgraded
08/12/26
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (NASDAQ: MNPR), Achieve Life Sciences (NASDAQ: ACHV) and OptimizeRx (NASDAQ: OPRX)
Lake Street Analyst forecast on DE:1IY0
Chad Messer
Lake Street
Lake Street
€88.97
Buy
-2.34%
Downside
Reiterated
06/30/26
Monopar Therapeutics Inc (MNPR) Gets a Buy from Lake Street
Piper Sandler Analyst forecast on DE:1IY0
Biren Amin
Piper Sandler
Piper Sandler
€87.24
Buy
-4.24%
Downside
Reiterated
06/29/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Leerink Partners Analyst forecast on DE:1IY0
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
€99.33
Buy
9.04%
Upside
Reiterated
05/15/26
Leerink Partners Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)
Raymond James Analyst forecast on DE:1IY0
Christopher Raymond
Raymond James
Raymond James
€122.66→€106.24
Buy
16.62%
Upside
Reiterated
11/14/25
Monopar downgraded to Outperform from Strong Buy at Raymond JamesMonopar downgraded to Outperform from Strong Buy at Raymond James
Chardan Capital Analyst forecast on DE:1IY0
Keay Nakae
Chardan Capital
Chardan Capital
€51.83→€73.42
Buy
-19.41%
Downside
Reiterated
09/25/25
Monopar Therapeutics price target raised to $85 from $60 at ChardanMonopar Therapeutics price target raised to $85 from $60 at Chardan
Brookline Capital Markets Analyst forecast on DE:1IY0
Kemp Dolliver
Brookline Capital Markets
Brookline Capital Markets
€44.92→€80.33
Buy
-11.82%
Downside
Reiterated
09/25/25
Brookline Capital Markets Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Monopar Therapeutics Inc

3 Months
Andres Y. MaldonadoH.C. Wainwright
Success Rate
8/10 ratings generated profit
80%
Average Return
+47.72%
Copying Andres Y. Maldonado's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +47.72% per trade.
1 Year
Andres Y. MaldonadoH.C. Wainwright
Success Rate
10/10 ratings generated profit
100%
Average Return
+90.44%
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +90.44% per trade.
2 Years
Biren AminPiper Sandler
Success Rate
7/7 ratings generated profit
100%
Average Return
+125.40%
Copying Biren Amin's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +125.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1IY0 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
11
17
17
12
4
Buy
0
0
5
10
15
Hold
0
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
18
23
23
20
In the current month, 1IY0 has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1IY0 average Analyst price target in the past 3 months is 104.62.
Each month's total comprises the sum of three months' worth of ratings.

1IY0 Financial Forecast

1IY0 Earnings Forecast

Next quarter’s earnings estimate for 1IY0 is -€0.69 with a range of -€1.18 to -€0.32. The previous quarter’s EPS was -€0.53. 1IY0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1IY0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1IY0 is -€0.69 with a range of -€1.18 to -€0.32. The previous quarter’s EPS was -€0.53. 1IY0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1IY0 has Performed in-line its overall industry.
No data currently available

1IY0 Sales Forecast

Next quarter’s sales forecast for 1IY0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 1IY0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1IY0 has Performed in-line its overall industry.
Next quarter’s sales forecast for 1IY0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 1IY0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1IY0 has Performed in-line its overall industry.

1IY0 Stock Forecast FAQ

What is DE:1IY0’s average 12-month price target, according to analysts?
Based on analyst ratings, Monopar Therapeutics Inc’s 12-month average price target is 104.62.
    What is DE:1IY0’s upside potential, based on the analysts’ average price target?
    Monopar Therapeutics Inc has 14.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Monopar Therapeutics Inc a Buy, Sell or Hold?
          Monopar Therapeutics Inc has a consensus rating of Strong Buy, which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Monopar Therapeutics Inc’s share price target?
            The average share price target for Monopar Therapeutics Inc is 104.62. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €114.88 ,and the lowest forecast is €87.24. The average share price target represents 14.85% Increase from the current price of €91.1.
              What do analysts say about Monopar Therapeutics Inc?
              Monopar Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Monopar Therapeutics Inc?
                To buy shares of DE:1IY0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.